RNA Genetic Sequencing Identifies People Who Are High-Risk for Cancer but Would Have Been Missed by DNA Testing Alone with Carrie Horton, MS, CGC

• Join us to learn about the newly published study highlighting the findings of a study that showed paired RNA and DNA genetic testing detected elusive pathogenic variants in 1 out of every 950 people that did not appear in DNA testing alone. The findings, published in Nature Partner Journal Genomic Medicine, highlight the importance of combining RNA and DNA genetic testing to give clinicians and their patients the most accurate and comprehensive genetic data needed to inform patient care and achieve the best outcomes.

Carrie Horton, MS, CGC | Presenter

Sr. Clinical Research Specialist - Oncology, Ambry Genetics

Ms. Horton received her M.S. in Genetic Counseling from Arcadia University and practiced clinically as a cancer genetic counselor in Memphis, TN prior to joining Ambry Genetics 6 years ago. As a reporting genetic counselor at Ambry, she performed variant assessment, generated reports for oncology tests, and curated clinical literature for report content. In her current role as Sr. Clinical Research Specialist, she designs and conducts studies focusing on the translational application of Ambry's research. Ms. Horton's research interests include improving the clinical utility of and increasing access to genetic testing.

Rachid Karam, MD, PhD | Moderator

Director of Clinical and Translational Research, Ambry Genetics

Rachid Karam obtained his M.D. in 2003, in Brazil, and his Ph.D. in Oncogenetics in 2008, at the University of Porto, Portugal. He did his postdoctoral studies at the University of California, San Diego (UCSD) from 2009 to 2014. He joined Ambry Genetics in 2014, and is now Ambry’s Director of Clinical and Translational Research. He also actively participates in several NIH/ClinGen committees dedicated to creating guidelines for the interpretation of genetic testing and is currently the Co-Chair of the CDH1 ClinGen expert panel.